TRANSLATING A DEEP
EXPERTISE IN GROWTH
FACTOR BIOLOGY INTO
INNOVATIVE THERAPIES
Restoring organ function Read more
Modulating growth
factor pathways to
repair tissue
structures
Restoring organ function Read more
Building Agomab
to treat fibrotic
related diseases
Restoring organ function Read more

Modulating growth factor signaling through precise and novel treatments

Our goal is to preserve and restore organ function in a range of acute and chronic conditions associated with tissue injury, inflammation, fibrosis and degeneration.
About Us

Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas

News & Events
PR

AGOMAB REPORTS POSITIVE PHASE 1 RESULTS WITH AGMB-129, A GI-RESTRICTED ALK5 INHIBITOR FOR FIBROSTENOSING CROHN’S DISEASE

February 2nd 2023
Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD).

PR

Agomab Therapeutics Selected as One of Fierce Biotech's ``Fierce 15`` Companies of 2022

September 2022

“We are determined to improve the lives of patients through innovation. With a broad European footprint, we have built a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”

-

Tim Knotnerus, Chief Executive Officer